Table of Contents
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the anticonvulsants market
- Related reports
- Upcoming related reports
MARKET DEFINITION
- Market definition for this report
MARKET OVERVIEW
- Seven major markets
- Current and future market overview
- Opportunities and threats
- US
- Current and future market assessment
- Opportunities and threats
- Japan
- Current and future market assessment
- Opportunities and threats
- Five major European markets (5EU)
- Current and future market assessment
- Opportunities and threats
- France
- Current and future market assessment
- Germany
- Current and future market assessment
- Italy
- Current and future market assessment
- Spain
- Current and future market assessment
- UK
- Current and future market assessment
- Global and rest of the world snapshot
- Current market assessment
- Opportunity within the rest of the world market
BRAND DYNAMICS
- Overview of competitive landscape
- Lyrica is set to usurp Topamax' s status as market leader
- US formulary tier status for leading brands
- Availability of generic first-generation anticonvulsants negatively
impacts brand tier status
- Trends in marketing strategies
- Promotional spend
- Sponsorship of patient education/partnerships
- Direct-to-consumer advertising
- Topamax (topiramate; Johnson & Johnson)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Lyrica (pregabalin; Pfizer)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Lamictal and Lamictal XR (lamotrigine; GlaxoSmithKline)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Keppra and Keppra XR (levetiracetam; UCB)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Depakote franchise (valproate semisodium; Abbott)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Vimpat (lacosamide; UCB)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Banzel (rufinamide; Eisai)
- Drug profile
- Product positioning
- SWOT analysis
- Brand forecast to 2018
- Stedesa/Zebinix (eslicarbazepine acetate; Sepracor/Eisai)
- Drug profile
- Product positioning
- Brand forecast to 2018
- Other marketed anticonvulsant drugs
- Pipeline anticonvulsants
- Carisbamate (Johnson & Johnson)
- Brivaracetam (UCB)
- Retigabine (Valeant/GlaxoSmithKline)
- Perampanel (E2007; Eisai)
KEY DEVELOPERS
- Strategic overview
- Leading companies in the branded anticonvulsant class market
- Trends in corporate strategy
- Indication expansion
- Development of extended release formulations
- Recent shifts in corporate strategy
- Interest in the Japanese market has increased among marketers
- Recent strategic partnerships
- Key players seek co-promotional deals to expand geographical reach of
brands
- Eisai
- Corporate strategy
- Anticonvulsant portfolio assessment
- UCB
- Corporate strategy
- Anticonvulsant portfolio assessment
CASE STUDIES
- Introduction
- Indication expansion strategies
- Migraine prophylaxis offers a large patient potential
- Fibromyalgia - EMEA thwarts market approval
- Anxiety disorders - a less profitable indication for anticonvulsant
manufacturers despite substantial patient potential
- Pediatric epilepsy indication expansions generate brand loyalty
BIBLIOGRAPHY
- Journal papers
- Publications
- Websites
- Datamonitor reports
APPENDIX A - MARKET ASSUMPTIONS
- New product launches
- Patent expiries
- Data definitions, limitations and assumptions
- Standard units
- Country group definitions
- Derivation of sales forecasts and pricing trends
- Forecast methodology
APPENDIX B
- Contributing experts
- Conferences attended
- Report methodology
TABLES
- Table: Key events impacting the anticonvulsant class market, 2009 - 2018
- Table: Sales and growth of key anticonvulsant brands in the seven major
markets, 2008 - 2018
- Table: Sales forecasts of key anticonvulsant drugs in the seven major
markets ($m), 2008 - 2018
- Table: Summary of opportunities and threats in the anticonvulsants market
across the seven major markets, 2009 - 2018
- Table: Sales and growth of key anticonvulsant brands in the US, 2008 - 2018
- Table: US sales forecasts of anticonvulsant drugs ($m), 2008 - 2018
- Table: Summary of opportunities and threats in the anticonvulsants market
in the US, 2009 - 2018
- Table: Sales and growth of anticonvulsant drugs in Japan, 2004 - 08
- Table: Sales and growth of key anticonvulsant brands in Japan , 2008 - 2018
- Table: Sales forecasts of branded anticonvulsants in Japan ($m), 2008 -
2018
- Table: Summary of opportunities and threats in the Japanese
anticonvulsants market, 2009 - 2018
- Table: Sales and growth of the anticonvulsant drug class in the 5EU, 2004
- 2018
- Table: Sales forecasts of branded anticonvulsants in the 5EU ($m), 2008 -
2018
- Table: Summary of opportunities and threats in the five major European
markets, 2009
- Table: Sales and growth of key anticonvulsant brands in France , 2008 -
2018
- Table: Sales and growth of key anticonvulsant brands in Germany, 2008 -
2018
- Table: Sales and growth of key anticonvulsant brands in Italy, 2008 - 2018
- Table: Sales and growth of key anticonvulsant brands in Spain, 2008 - 2018
- Table: Sales and growth of key anticonvulsant brands in Spain, 2008 - 2018
- Table: Global sales ($m) dynamics of the anticonvulsant class market, 2004
- 08
- Table: Comparison of leading anticonvulsant brand sales in the seven major
markets and the rest of the world, 2004 - 08
- Table: Sales of established and recently launched anticonvulsant brands in
the seven major markets ($m), 2008 - 2018
- Table: Key anticonvulsants in late-stage R&D, 2009
- Table: Representative formulary tier status in the US for leading
anticonvulsant brands, 2009
- Table: Marketing strategies employed by the companies behind the top five
anticonvulsant brands, 2009
- Table: Topamax (topiramate): key facts, 2009
- Table: Impacting factors on the revenues of Topamax, 2009 - 2018
- Table: Lyrica (pregabalin): key facts, 2009
- Table: Impacting factors on the revenues of Lyrica, 2009 - 2018
- Table: Lamictal (lamotrigine): key facts, 2009
- Table: Impacting factors on the revenues of Lamictal/Lamictal XR, 2009 -
2018
- Table: Keppra (levetiracetam): key facts, 2009
- Table: Impacting factors on the revenues of Keppra franchise, 2009 - 2018
- Table: Depakote (valproate semisodium): key facts, 2009
- Table: Impacting factors on the revenues of Depakote franchise, 2009 - 2018
- Table: Vimpat (lacosamide): key facts, 2009
- Table: Impacting factors on the revenues of Vimpat, 2009 - 2018
- Table: Banzel (rufinamide): key facts, 2009
- Table: Impacting factors on the revenues of Banzel, 2009 - 2018
- Table: Eslicarbazepine acetate (Stedesa/Zebinix): key facts, 2009
- Table: Summary of all other marketed anticonvulsant drugs, 2009
- Table: Carisbamate - target product profile, 2009
- Table: Key facts: Phase II trial of carisbamate in diabetic neuropathic
pain
- Table: Key factors impacting sales of carisbamate, 2009 - 2018
- Table: Brivaracetam - target product profile, 2009
- Table: Ongoing clinical trial summary for UCB' s brivaracetam, 2009
- Table: Key factors impacting sales of brivaracetam, 2009 - 2018
- Table: Retigabine - target product profile, 2009
- Table: Key factors impacting sales of retigabine, 2009 - 2018
- Table: Perampanel - target product profile, 2009
- Table: Development status of Eisai' s perampanel, 2009
- Table: Key factors impacting sales of perampanel, 2009 - 2018
- Table: Leading companies in the branded seven major anticonvulsant market
by sales value, 2008 - 2018
- Table: Key strategic deals and events in the antidepressant market, 2009
- Table: Eisai portfolio assessment of anticonvulsants, 2009 - 18
- Table: UCB' s portfolio assessment of anticonvulsants, 2009
- Table: Product launch and indication expansion dates for anticonvulsants
across the seven major markets, 2009 - 2018
- Table: Patent expiry dates for marketed anticonvulsant drugs in the seven
major markets, 2009 - 2018
FIGURES
- Figure: Indexed anticonvulsant drug sales in the seven major markets by
region ($m), 2004 - 08
- Figure: Key events impacting the anticonvulsants drug class market, 2004 -
08
- Figure: Anticonvulsant market forecast across the seven major markets by
region ($m), 2008 - 2018
- Figure: Primary and secondary indications for anticonvulsants
- Figure: Topamax (topiramate) total brand sales by indication in the seven
major markets ($m), 2004 - 08
- Figure: Dynamics of the top five anticonvulsants in the US, 2004 - 08
- Figure: US anticonvulsant market forecast, 2008 - 2018
- Figure: Epilepsy-specific sales of Trileptal (oxcarbazepine) in the US
between Q1 2007 and Q4 2008
- Figure: Change in Japanese market anticonvulsant class sales value ($),
2004 - 08
- Figure: Japanese anticonvulsant market sales forecast, 2008 - 18
- Figure: Population of Japan over the age of 65 years (millions), 1950 -
2020
- Figure: Dynamics of anticonvulsant drug class markets within the 5EU ($m),
2004 - 08
- Figure: 5EU anticonvulsant market sales forecast, split by country, 2008 -
18
- Figure: IMS standard unit price point of three leading anticonvulsant
brands in the 5EU ($), 2008
- Figure: Change anticonvulsant market class sales value ($) in France, 2004
- 08
- Figure: French anticonvulsant market sales forecast, 2008 - 18
- Figure: Change anticonvulsant market class sales value ($) in Germany,
2004 - 08
- Figure: German anticonvulsant market sales forecast, 2008 - 18
- Figure: Change anticonvulsant market class sales value ($) in Italy, 2004
- 08
- Figure: Italian anticonvulsant market sales forecast, 2008 - 18
- Figure: Change anticonvulsant market class sales value ($) in Spain, 2004
- 08
- Figure: Spanish anticonvulsant market sales forecast, 2008 - 18
- Figure: Change anticonvulsant market class sales value ($) in the UK, 2004
- 08
- Figure: UK anticonvulsant market sales forecast, 2008 - 18
- Figure: Change in global anticonvulsant market sales value by region, 2004
- 08
- Figure: Change in global anticonvulsant market sales by value by region,
2004 - 08
- Figure: Change in global anticonvulsant market sales volume,( IMS standard
units sold, 2004 - 08
- Figure: Global anticonvulsant class market sales volume (IMS standard
units sold) and sales value ($), by region, 2008
- Figure: Global anticonvulsant class market sales volume (IMS standard
units sold) and sales value ($), by region, 2008
- Figure: Non-direct consumer promotional spend for four five key
anticonvulsant brands in the US and 5EU, Q2 2007 - Q2 2008
- Figure: Screenshot of Johnson & Johnson' s promotion of Topamax' s coupon
card scheme
- Figure: Screenshot of UCB' s patient savings programs for Keppra XR and
Vimpat
- Figure: Screenshot of Eisai' s patient assistance program for Banzel
- Figure: Topamax (topiramate; Johnson & Johnson) sales volume by condition
in the seven major markets, 2008
- Figure: Topamax SWOT analysis, 2009
- Figure: Topamax sales ($m) forecast across the seven major markets ($m),
2008 - 2018
- Figure: Lyrica sales volume split by condition in the US and 5EU, 2008
- Figure: Lyrica SWOT analysis, 2009
- Figure: Lyrica sales($m) forecast across the seven major markets ($m),
2008 - 2018
- Figure: Lamictal sales volume by condition in the seven major markets, 2008
- Figure: Lamictal SWOT analysis
- Figure: Lamictal and Lamictal XR sales across the seven major markets
($m), 2008 - 2018
- Figure: Keppra (levetiracetam, UCB) sales volume split by condition in the
US and 5EU, 2008
- Figure: Keppra/Keppra XR SWOT analysis, 2009
- Figure: Keppra and Keppra XR sales ($m) forecast across the seven major
markets ($m), 2008 - 2018
- Figure: Indexed seven major market sales of Depakote franchise, 2004 - 08
- Figure: Depakote SWOT analysis, 2009
- Figure: Depakote and Depakote ER sales across the seven major markets
($m), 2008 - 2018
- Figure: Vimpat (lacosamide) SWOT analysis, 2009
- Figure: Vimpat sales by country in the seven major markets ($m), 2008 -
2018
- Figure: Banzel SWOT analysis, 2009
- Figure: Banzel sales ($m) forecast by country in the seven major markets
($m), 2008 - 2018
- Figure: Eslicarbazepine acetate (Stedesa/Zebinix) sales by country in the
seven major markets ($m), 2008 - 2018
- Figure: Carisbamate' s epilepsy-specific sales forecast in the US and 5EU,
split by country ($m), 2009 - 2018
- Figure: Brivaracetam' s sales forecast in epilepsy in the US and 5EU, split
by country ($m), 2009 - 2018
- Figure: Retigabine' s epilepsy-specific sales in the US and 5EU, split by
country ($m), 2009 - 2018
- Figure: Perampanel' s sales in epilepsy in the seven major markets split by
country ($m), 2009 - 2018
- Figure: Sales value dynamics of the top eight branded anticonvulsant class
market companies by seven major market revenues ($m), 2004 - 08
- Figure: Migraine-specific sales of Topamax across the seven major markets
($m), 2004 - 08
- Figure: Fibromyalgia-specific sales of Lyrica across the seven major
markets ($m), 2004 - 08
- Figure: Keppra' s epilepsy indication expansions
- Figure: Epilepsy-specific sales of Keppra and Lyrica across the seven
major markets ($m), 2004 - 08
|
Related Report
|
View Cart
